MicroRNA-1307-3p contributes to breast cancer progression through PRM2

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Breast cancer (BC) remains a leading global cancer in women.
• MicroRNA (miRNA) dysregulation is implicated in BC development.
• miR-1307-3p is upregulated in BC, but its functions and targets are not fully understood.

Purpose of the Study:

• To investigate the role of miR-1307-3p in BC cell proliferation, migration, invasion, and angiogenesis.
• To identify and validate target genes of miR-1307-3p in BC.

Main Methods:

• Quantitative real-time reverse transcription-PCR (RT-qPCR) to measure miR-1307-3p levels.
• Assessment of BC cell behavior following miR-1307-3p inhibition.
• Bioinformatic analysis and experimental validation (Western blot, dual-luciferase assays) to identify and confirm miR-1307-3p targets.

Main Results:

• Inhibition of miR-1307-3p significantly suppressed BC cell proliferation, migration, invasion, and angiogenesis.
• Bioinformatics predicted 17 potential targets for miR-1307-3p.
• Protamine 2 (PRM2) was confirmed as a direct target gene of miR-1307-3p.

Conclusions:

• Overexpression of miR-1307-3p drives key hallmarks of breast cancer progression.
• PRM2 is identified as a novel target of miR-1307-3p in the context of breast cancer.
• Targeting miR-1307-3p and its downstream effectors like PRM2 may represent a therapeutic avenue for BC.